Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors.

11005 Background: Remote therapeutic monitoring (RTM) using electronic patient-reported outcomes (ePROs) may help care teams respond earlier to patient needs and potentially avoid acute care events, but evidence from real-world practice is limited. This study evaluates the impact of using the Canopy ePRO-based RTM platform on acute care events. Methods: We studied 1,549 patients with metastatic solid tumor malignancies receiving systemic treatment at 5 community oncology sites between Jan 1, 2024 until July 20, 2025. Patients were invited to complete weekly ePRO symptom surveys. Symptoms that exceeded pre-specified severity thresholds triggered notifications to a dedicated triage nursing staff for evaluation and consideration of telephonic triage, urgent outpatient office evaluation or referral to the emergency department or hospital. Patients who enrolled and submitted ≥ 2 ePRO surveys within 45 days of first treatment were included in the RTM group, while those not enrolled or who did not submit 2 or more reports were in the control group. Hospitalization events were extracted from the Arkansas health information exchange. Inverse probability of treatment weighting was used to account for potential non-random selection of patients into the RTM group when performing statistical tests of difference, and achieved cohort balance in terms of age at index, time from first cancer diagnosis to treatment, site of cancer, sex, and race. Results: Over 18 months following first anticancer treatment through data cutoff date, 558 patients were in the RTM group compared to 991 patients in the control group. Among patients in the RTM group, 9.0% had a record of hospitalization compared to 13% in the control group, representing a 28% reduction (risk difference: -3.63, 95% CI -7.06 to -0.39, p: 0.032); 12% of patients in the RTM group had record of ED visit compared to 13% in the control group (risk difference: -1.77, 95% CI: -5.24 to 1.63, p: 0.310). The estimated cost savings per 1,000 patients/years utilizing RTM during treatment was $3,192,789 for hospitalizations and $93,330 for emergency department visits. Conclusions: RTM utilization with Canopy is associated with fewer hospitalizations and potentially fewer emergency visits compared to traditional outpatient management of patients with metastatic solid tumors, potentially reducing the cost of care. Prompt notification of patient symptoms resulting in preemptive treatment may help patients avoid acute care events. Unweighted clinical and demographic characteristics. Characteristic Enrolled & ActiveN = 558 Not EnrolledN = 991 Age at index 64 (55, 71) 70 (62, 78) Sex - Female 313 (56%) 515 (52%) Race/Ethnicity - White 484 (87%) 846 (85%) Race/Ethnicity - Hispanic 28 (5.0%) 58 (5.9%) Lung Cancer 131 (23%) 179 (18%) Breast cancer 98 (18%) 219 (22%) Colorectal cancer 88 (16%) 148 (15%)